Karyopharm Therap (NASDAQ: KPTI) reported Q2 EPS of ($1.02), $0.52 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Karyopharm Therap (KPTI) click here.